Lanean...
COVID-19 and Disease-Modifying Anti-rheumatic Drugs
PURPOSE OF REVIEW: Patients on disease-modifying anti-rheumatic drugs (DMARDs) remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several DMARDs have been proposed as COVID-19 therapies. RECENT FINDINGS: In patients with autoimmune diseases, baseline glucocorticoid use is...
Gorde:
| Argitaratua izan da: | Curr Rheumatol Rep |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer US
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8065312/ https://ncbi.nlm.nih.gov/pubmed/33893890 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11926-021-00998-9 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|